Editor’s Note
**Editor’s Note:** This article highlights Jeis’ strategic expansion into the Philippines, following FDA product approval and the establishment of a local supply foundation. With three e.p.t.q. product variants set to launch, the company aims to strengthen its presence in Southeast Asia’s growing aesthetic market.
[Biotimes] Global aesthetic and biopharmaceutical company Jeisys Medical has obtained product approval for its hyaluronic acid (HA) filler ‘e.p.t.q. Lidocaine’ in the Philippines, marking a step toward expanding its presence in the Southeast Asian market.
Jeisys Medical announced on the 24th that it received product approval from the Philippine Food and Drug Administration (FDA) for three variants of ‘e.p.t.q. Lidocaine’: S100, S300, and S500.
With this approval, Jeisys Medical has secured a foundation to supply the e.p.t.q. product line in the Philippine market, and plans to accelerate local business expansion and Southeast Asian market penetration.
The approved products are hyaluronic acid fillers containing the local anesthetic lidocaine, used to reduce pain during procedures while improving wrinkles and restoring facial volume.
Jeisys Medical aims to strengthen local partnerships, gradually expand product supply, and enhance brand competitiveness in the Philippines and broader Southeast Asian market through sales and marketing strategies tailored to each country’s market characteristics.